Berek JS - Search Results

1

Monoclonal antibody therapy of ovarian cancer.

Nicodemus CF, Berek JS. Nicodemus CF, et al. Among authors: berek js. Expert Rev Anticancer Ther. 2005 Feb;5(1):87-96. doi: 10.1586/14737140.5.1.87. Expert Rev Anticancer Ther. 2005. PMID: 15757441 Review.

2

Specific keynote: immunological therapy for ovarian cancer.

Berek JS, Dorigo O, Schultes B, Nicodemus C. Berek JS, et al. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S105-9; discussion S110-3. doi: 10.1006/gyno.2002.6695. Gynecol Oncol. 2003. PMID: 12586097 Review. No abstract available.

3

Biologic and immunologic therapies for ovarian cancer.

Berek JS, Schultes BC, Nicodemus CF. Berek JS, et al. J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s. doi: 10.1200/JCO.2003.01.517. J Clin Oncol. 2003. PMID: 12743131 Review.

4

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.

Berek JS. Berek JS. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65. doi: 10.1517/14712598.4.7.1159. Expert Opin Biol Ther. 2004. PMID: 15268682 Review.

5

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Berek JS, et al. J Clin Oncol. 2004 Sep 1;22(17):3507-16. doi: 10.1200/JCO.2004.09.016. J Clin Oncol. 2004. PMID: 15337799 Clinical Trial.

6

Intraperitoneal chemotherapy for ovarian cancer.

Hamilton CA, Berek JS. Hamilton CA, et al. Among authors: berek js. Curr Opin Oncol. 2006 Sep;18(5):507-15. doi: 10.1097/01.cco.0000239892.21161.18. Curr Opin Oncol. 2006. PMID: 16894301 Review.

7

Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.

Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Ashworth A, et al. Among authors: berek js. Gynecol Oncol. 2008 Mar;108(3):652-7. doi: 10.1016/j.ygyno.2007.11.014. Epub 2007 Dec 21. Gynecol Oncol. 2008. PMID: 18096210

8

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer.

Berek JS, Taylor PT, Nicodemus CF. Berek JS, et al. J Immunother. 2008 Feb-Mar;31(2):207-14. doi: 10.1097/CJI.0b013e31816060ce. J Immunother. 2008. PMID: 18481390 Clinical Trial.

9

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.

Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Berek J, et al. J Clin Oncol. 2009 Jan 20;27(3):418-25. doi: 10.1200/JCO.2008.17.8400. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075271 Clinical Trial.

10

Abagovomab for ovarian cancer.

Pfisterer J, Harter P, Simonelli C, Peters M, Berek J, Sabbatini P, du Bois A. Pfisterer J, et al. Expert Opin Biol Ther. 2011 Mar;11(3):395-403. doi: 10.1517/14712598.2011.553598. Epub 2011 Jan 18. Expert Opin Biol Ther. 2011. PMID: 21241213 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results